Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lisdexamfetamine dimesylate

Mobilizing Agitation Detection in Children with ADHD

Marius Rus, founder of StressLess–the startup behind Tully–discusses wearable technologies for children with ADHD, autism, and other mental health conditions. He also shares his tips and lessons learned from founding...

Impetus Digital

- PMLiVE

Healthware Group report on depression care in Italy highlights need for digital therapeutics

Mental health disorders are the fifth leading cause of disability adjusted life years in Italy

Mobilizing Agitation Detection in Children with ADHD

Marius Rus, founder of StressLess–the startup behind Tully–discusses wearable technologies for children with ADHD, autism, and other mental health conditions. He also shares his tips and lessons learned from founding...

Impetus Digital

- PMLiVE

Mental Health Awareness Week

This year the theme of Mental Health Awareness Week is loneliness, focusing on the impact of it on our mental health and the practical steps we can take to address...

Mednet Group

- PMLiVE

Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3

Biogen and Sage signed a $3.1bn deal last year to jointly develop potential depression therapies

Supporting Mental Health During a Global Pandemic

Sam Duboc, Chair & CEO of MindBeacon, explores virtual care and telehealth for treating depression, anxiety, addiction, and other conditions; mental health issues brought on by COVID-19; and how to...

Impetus Digital

- PMLiVE

Biogen signs $3.1bn deal with Sage for potential depression therapies

Zuranolone already has a breakthrough therapy designation from the US FDA

- PMLiVE

Takeda to sell Japan consumer health unit for $2.3bn

Deal helps to reduce debt accrued from Shire takeover

- PMLiVE

Acadia’s Nuplazid misses the mark in major depressive disorder trial

Company's efforts to extend drug's reach fall flat

Impetus Digital Fireside Chat with with Jon Sockell, Co-Founder/COO of Limbix

Jon Sockell, Co-founder and COO of Limbix, sits down with us in this Fireside Chat. See how Limbix is paving the way for prescription digital therapeutics and learn from their trials,...

Impetus Digital

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

NICE knocks back J&J’s depression nasal spray Spravato

Cites clinical and pricing uncertainty as basis of rejection

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links